Lupin Limited (Lupin) has announced the acquisition of huminsulin® in India from Eli Lilly and Company (Lilly), marking a significant step in the company’s strategy to enhance its diabetes portfolio.
Lupin has been distributing and promoting the huminsulin range, which includes insulin human products such as huminsulin R, huminsulin NPH, huminsulin 50/50, and huminsulin 30/70, through distribution and promotion agreements with Lilly in India.
A Key Addition to Lupin’s Diabetes Care Offerings
The Huminsulin range is widely used for the treatment of both type 1 and type 2 diabetes mellitus.
The products are essential for improving blood sugar control in adults and children alike.
Insulin treatment is critical for managing type 1 diabetes and often becomes necessary for type 2 diabetes as the disease progresses.
With a large population in India affected by diabetes, both type 1 and type 2, doctors prescribe Insulin Human to manage the condition alongside other therapies.
Strategic Acquisition to Expand Diabetes Care
As reported by equitybulls.com, the acquisition is a strategic move by Lupin to further broaden its diabetes care portfolio.
Nilesh Gupta, Managing Director, Lupin stated, “The acquisition strengthens our ongoing efforts to provide high-quality, affordable healthcare to our patients. It also reinforces our commitment to combating diabetes and offering comprehensive care.”
Strengthening Lupin’s Diabetes Portfolio
Rajeev Sibal, President of India Region Formulations at Lupin, added, “Lupin has always been a leader in providing holistic diabetes care to patients. This acquisition further solidifies our position. It allows us to offer a wider range of human insulin options to millions of patients, helping them lead healthier lives.”
